AI Personalized Vaccine Sequence Design Engine VaxiCore Released: From Genome to Vaccine Formulation in 48 Hours
VaxiCore engine analyzes patient tumor genome mutation profiles and automatically generates personalized mRNA vaccine sequences within 48 hours, currently in clinical Phase II for melanoma and lung cancer.
Boston-based biotech company VaxiCore released its namesake AI vaccine design engine on February 28. The system completes the entire workflow from patient tumor genome sequencing to personalized mRNA vaccine sequence design in 48 hours — a process that previously took 4 to 6 weeks.
VaxiCore operates in three steps: first, whole-exome sequencing data is extracted from tumor biopsy samples to identify neoantigen mutations; then deep learning models predict which mutant peptide segments are most likely to trigger strong T-cell immune responses; finally, mRNA sequences are optimized for codons and secondary structure to maximize translation efficiency in the human body.
In interim data from a melanoma clinical Phase II trial, patients using VaxiCore-designed personalized vaccines achieved a 12-month progression-free survival rate of 71%, compared to 34% for the standard chemotherapy control group. The engine is currently in use at five cancer centers in Boston, London, and Singapore.
VaxiCore charges $12,000 per personalized vaccine design, excluding subsequent mRNA synthesis and clinical injection costs. The company says it is negotiating coverage plans with insurers.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.